Specificity of serological screening tests and reference laboratory tests to diagnose gambiense human African trypanosomiasis: a prospective clinical performance study.
Humans
Trypanosomiasis, African
/ diagnosis
Sensitivity and Specificity
Cote d'Ivoire
Trypanosoma brucei gambiense
/ immunology
Adult
Guinea
Prospective Studies
Male
Adolescent
Female
Young Adult
Middle Aged
Serologic Tests
/ methods
Child
Enzyme-Linked Immunosorbent Assay
/ methods
Aged
Child, Preschool
Antibodies, Protozoan
/ blood
Trypanosoma brucei gambiense
Diagnosis
Human African trypanosomiasis
Immunological test
Molecular test
Rapid diagnostic test
Specificity
Journal
Infectious diseases of poverty
ISSN: 2049-9957
Titre abrégé: Infect Dis Poverty
Pays: England
ID NLM: 101606645
Informations de publication
Date de publication:
08 Jul 2024
08 Jul 2024
Historique:
received:
19
04
2024
accepted:
25
06
2024
medline:
9
7
2024
pubmed:
9
7
2024
entrez:
8
7
2024
Statut:
epublish
Résumé
Serological screening tests play a crucial role to diagnose gambiense human African trypanosomiasis (gHAT). Presently, they preselect individuals for microscopic confirmation, but in future "screen and treat" strategies they will identify individuals for treatment. Variability in reported specificities, the development of new rapid diagnostic tests (RDT) and the hypothesis that malaria infection may decrease RDT specificity led us to evaluate the specificity of 5 gHAT screening tests. During active screening, venous blood samples from 1095 individuals from Côte d'Ivoire and Guinea were tested consecutively with commercial (CATT, HAT Sero-K-SeT, Abbott Bioline HAT 2.0) and prototype (DCN HAT RDT, HAT Sero-K-SeT 2.0) gHAT screening tests and with a malaria RDT. Individuals with ≥ 1 positive gHAT screening test underwent microscopy and further immunological (trypanolysis with T.b. gambiense LiTat 1.3, 1.5 and 1.6; indirect ELISA/T.b. gambiense; T.b. gambiense inhibition ELISA with T.b. gambiense LiTat 1.3 and 1.5 VSG) and molecular reference laboratory tests (PCR TBRN3, 18S and TgsGP; SHERLOCK 18S Tids, 7SL Zoon, and TgsGP; Trypanozoon S One gHAT case was diagnosed. Overall test specificities (n = 1094) were: CATT 98.9% (95% CI: 98.1-99.4%); HAT Sero-K-SeT 86.7% (95% CI: 84.5-88.5%); Bioline HAT 2.0 82.1% (95% CI: 79.7-84.2%); DCN HAT RDT 78.2% (95% CI: 75.7-80.6%); and HAT Sero-K-SeT 2.0 78.4% (95% CI: 75.9-80.8%). In malaria positives, gHAT screening tests appeared less specific, but the difference was significant only in Guinea for Abbott Bioline HAT 2.0 (P = 0.03) and HAT Sero-K-Set 2.0 (P = 0.0006). The specificities of immunological and molecular laboratory tests in gHAT seropositives were 98.7-100% (n = 399) and 93.0-100% (n = 302), respectively. Among 44 reference laboratory test positives, only the confirmed gHAT patient and one screening test seropositive combined immunological and molecular reference laboratory test positivity. Although a minor effect of malaria cannot be excluded, gHAT RDT specificities are far below the 95% minimal specificity stipulated by the WHO target product profile for a simple diagnostic tool to identify individuals eligible for treatment. Unless specificity is improved, an RDT-based "screen and treat" strategy would result in massive overtreatment. In view of their inconsistent results, additional comparative evaluations of the diagnostic performance of reference laboratory tests are indicated for better identifying, among screening test positives, those at increased suspicion for gHAT. The trial was retrospectively registered under NCT05466630 in clinicaltrials.gov on July 15 2022.
Sections du résumé
BACKGROUND
BACKGROUND
Serological screening tests play a crucial role to diagnose gambiense human African trypanosomiasis (gHAT). Presently, they preselect individuals for microscopic confirmation, but in future "screen and treat" strategies they will identify individuals for treatment. Variability in reported specificities, the development of new rapid diagnostic tests (RDT) and the hypothesis that malaria infection may decrease RDT specificity led us to evaluate the specificity of 5 gHAT screening tests.
METHODS
METHODS
During active screening, venous blood samples from 1095 individuals from Côte d'Ivoire and Guinea were tested consecutively with commercial (CATT, HAT Sero-K-SeT, Abbott Bioline HAT 2.0) and prototype (DCN HAT RDT, HAT Sero-K-SeT 2.0) gHAT screening tests and with a malaria RDT. Individuals with ≥ 1 positive gHAT screening test underwent microscopy and further immunological (trypanolysis with T.b. gambiense LiTat 1.3, 1.5 and 1.6; indirect ELISA/T.b. gambiense; T.b. gambiense inhibition ELISA with T.b. gambiense LiTat 1.3 and 1.5 VSG) and molecular reference laboratory tests (PCR TBRN3, 18S and TgsGP; SHERLOCK 18S Tids, 7SL Zoon, and TgsGP; Trypanozoon S
RESULTS
RESULTS
One gHAT case was diagnosed. Overall test specificities (n = 1094) were: CATT 98.9% (95% CI: 98.1-99.4%); HAT Sero-K-SeT 86.7% (95% CI: 84.5-88.5%); Bioline HAT 2.0 82.1% (95% CI: 79.7-84.2%); DCN HAT RDT 78.2% (95% CI: 75.7-80.6%); and HAT Sero-K-SeT 2.0 78.4% (95% CI: 75.9-80.8%). In malaria positives, gHAT screening tests appeared less specific, but the difference was significant only in Guinea for Abbott Bioline HAT 2.0 (P = 0.03) and HAT Sero-K-Set 2.0 (P = 0.0006). The specificities of immunological and molecular laboratory tests in gHAT seropositives were 98.7-100% (n = 399) and 93.0-100% (n = 302), respectively. Among 44 reference laboratory test positives, only the confirmed gHAT patient and one screening test seropositive combined immunological and molecular reference laboratory test positivity.
CONCLUSIONS
CONCLUSIONS
Although a minor effect of malaria cannot be excluded, gHAT RDT specificities are far below the 95% minimal specificity stipulated by the WHO target product profile for a simple diagnostic tool to identify individuals eligible for treatment. Unless specificity is improved, an RDT-based "screen and treat" strategy would result in massive overtreatment. In view of their inconsistent results, additional comparative evaluations of the diagnostic performance of reference laboratory tests are indicated for better identifying, among screening test positives, those at increased suspicion for gHAT.
TRIAL REGISTRATION
BACKGROUND
The trial was retrospectively registered under NCT05466630 in clinicaltrials.gov on July 15 2022.
Identifiants
pubmed: 38978124
doi: 10.1186/s40249-024-01220-5
pii: 10.1186/s40249-024-01220-5
doi:
Substances chimiques
Antibodies, Protozoan
0
Banques de données
ClinicalTrials.gov
['NCT05466630']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
53Subventions
Organisme : Swiss Agency for Development and Cooperation
ID : 81071426
Organisme : Swiss Agency for Development and Cooperation
ID : 7F-08866.03.01
Organisme : Bill & Melinda Gates Foundation
ID : INV-001785
Pays : United States
Organisme : Bill and Melinda Gates Foundation
ID : OPP1033712
Organisme : Bill and Melinda Gates Foundation
ID : OPP1154033
Organisme : Bill and Melinda Gates Foundation
ID : INV-031353
Informations de copyright
© 2024. The Author(s).
Références
World Health Organization. Working to overcome the global impact of neglected tropical diseases: first WHO report on neglected tropical diseases. Geneva: World Health Organization; 2010.
World Health Organization. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. Geneva: World Health Organization; 2021.
Camara O, Biéler S, Bucheton B, Kagbadouno M, MathuNdung’u J, Solano P, et al. Accelerating elimination of sleeping sickness from the Guinean littoral through enhanced screening in the post-Ebola context: a retrospective analysis. PLoS Negl Trop Dis. 2021;15:e0009163.
pubmed: 33591980
pmcid: 7909630
doi: 10.1371/journal.pntd.0009163
Kaba D, Koffi M, Kouakou L, N’Gouan EK, Djohan V, Courtin F, et al. Towards the sustainable elimination of gambiense human African trypanosomiasis in Côte d’Ivoire using an integrated approach. PLoS Negl Trop Dis. 2023;17:e0011514.
pubmed: 37523361
pmcid: 10443840
doi: 10.1371/journal.pntd.0011514
World Health Organization. Control and surveillance of human African trypanosomiasis: report of a WHO Expert Committee. Geneva: World Health Organization; 2013.
Priotto G, Franco J, Lejon V, Büscher P, Matovu E, Ndung’u J, et al. Target product profile: diagnostic test for Trypanosoma brucei gambiense. Bull World Health Organ. 2023;101:535–40.
pubmed: 37529027
pmcid: 10388149
doi: 10.2471/BLT.23.290172
Magnus E, Vervoort T, Van Meirvenne N. A card-agglutination test with stained trypanosomes (CATT) for the serological diagnosis of T. b. gambiense trypanosomiasis. Ann Soc Belg Med Trop. 1978;58:169–76.
pubmed: 747425
Mitashi P, Hasker E, Lejon V, Kande V, Muyembe JJ, Lutumba P, et al. Human African trypanosomiasis diagnosis in first-line health services of endemic countries, a systematic review. PLoS Negl Trop Dis. 2012;6:e1919.
pubmed: 23209860
pmcid: 3510092
doi: 10.1371/journal.pntd.0001919
Büscher P, Mertens P, Leclipteux T, Gilleman Q, Jacquet D, Mumba-Ngoyi D, et al. Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study. Lancet Glob Health. 2014;2:e359–63.
pubmed: 25103304
doi: 10.1016/S2214-109X(14)70203-7
Lumbala C, Biéler S, Kayembe S, Makabuza J, Ongarello S, Ndung’u JM. Prospective evaluation of a rapid diagnostic test for Trypanosoma brucei gambiense infection developed using recombinant antigens. PLoS Negl Trop Dis. 2018;12:e0006386.
pubmed: 29590116
pmcid: 5898764
doi: 10.1371/journal.pntd.0006386
Priotto G, Franco J, Lejon V, Büscher P, Matovu E, Ndung’u J, et al. Target product profile: Trypanosoma brucei gambiense test for low-prevalence settings. Bull World Health Organ. 2023;101:541–5.
pubmed: 37529025
pmcid: 10388146
doi: 10.2471/BLT.23.290176
Van Meirvenne N, Magnus E, Büscher P. Evaluation of variant specific trypanolysis tests for serodiagnosis of human infections with Trypanosoma brucei gambiense. Acta Trop. 1995;60:189–99.
pubmed: 8907397
doi: 10.1016/0001-706X(95)00127-Z
Koné M, Kaba D, Kaboré J, Thomas LF, Falzon LC, Koffi M, et al. Passive surveillance of human African trypanosomiasis in Côte d’Ivoire: understanding prevalence, clinical symptoms and signs, and diagnostic test characteristics. PLoS Negl Trop Dis. 2021;15:e0009656.
pubmed: 34460829
pmcid: 8432893
doi: 10.1371/journal.pntd.0009656
Geerts M, Van Reet N, Leyten S, Berghmans R, Rock KS, Coetzer THT, et al. Trypanosoma brucei gambiense -iELISA: a promising new test for the post-elimination monitoring of human African trypanosomiasis. Clin Infect Dis. 2021;73:e2477–83.
pubmed: 32856049
doi: 10.1093/cid/ciaa1264
Sima N, Dujeancourt-Henry A, Perlaza BL, Ungeheuer MN, Rotureau B, Glover L. SHERLOCK4HAT: A CRISPR-based tool kit for diagnosis of Human African Trypanosomiasis. eBioMedicine. 2022;85:104308.
pubmed: 36374773
pmcid: 9626900
doi: 10.1016/j.ebiom.2022.104308
Van Reet N, Patient Pyana P, Dehou S, Bebronne N, Deborggraeve S, Büscher P. Single nucleotide polymorphisms and copy-number variations in the Trypanosoma brucei repeat (TBR) sequence can be used to enhance amplification and genotyping of Trypanozoon strains. PLoS One. 2021;16:e0258711.
pubmed: 34695154
pmcid: 8544829
doi: 10.1371/journal.pone.0258711
Franco JR, Cecchi G, Paone M, Diarra A, Grout L, Kadima Ebeja A, et al. The elimination of human African trypanosomiasis: achievements in relation to WHO road map targets for 2020. PLoS Negl Trop Dis. 2022;16(1):e0010047.
pubmed: 35041668
pmcid: 8765662
doi: 10.1371/journal.pntd.0010047
Flight L, Julious SA. Practical guide to sample size calculations: non-inferiority and equivalence trials. Pharmaceut Statist. 2016;15:80–9.
doi: 10.1002/pst.1716
Camara O, Camara M, Lejon V, Ilboudo H, Sakande H, Léno M, et al. Immune trypanolysis test with blood spotted on filter paper for epidemiological surveillance of sleeping sickness. Trop Med Int Health. 2014;19:828–31.
pubmed: 24750463
doi: 10.1111/tmi.12316
Hasker E, Lutumba P, Mumba D, Lejon V, Büscher P, Kande V, et al. Diagnostic accuracy and feasibility of serological tests on filter paper samples for outbreak detection of T.b. gambiense human African trypanosomiasis. Am J Trop Med Hyg. 2010;83:374–9.
pubmed: 20682885
pmcid: 2911188
doi: 10.4269/ajtmh.2010.09-0735
Camara M, Soumah AM, Ilboudo H, Travaillé C, Clucas C, Cooper A, et al. Extravascular dermal trypanosomes in suspected and confirmed tcases of gambiense human African trypanosomiasis. Clin Infect Dis. 2021;73:12–20.
pubmed: 32638003
doi: 10.1093/cid/ciaa897
Deborggraeve S, Lejon V, Ekangu RA, Mumba Ngoyi D, Pati Pyana P, Ilunga M, et al. Diagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study. PLoS Negl Trop Dis. 2011;5:e972.
pubmed: 21364966
pmcid: 3042993
doi: 10.1371/journal.pntd.0000972
Radwanska M, Claes F, Magez S, Magnus E, Perez-Morga D, Pays E, et al. Novel primer sequences for polymerase chain reaction-based detection of Trypanosoma brucei gambiense. Am J Trop Med Hyg. 2002;67:289–95.
pubmed: 12408669
doi: 10.4269/ajtmh.2002.67.289
Büscher P, Mumba Ngoyi D, Kaboré J, Lejon V, Robays J, Jamonneau V, et al. Improved models of mini anion exchange centrifugation technique (mAECT) and modified single centrifugation (MSC) for sleeping sickness diagnosis and staging. PLoS Negl Trop Dis. 2009;3:e471.
pubmed: 19936296
pmcid: 2775158
doi: 10.1371/journal.pntd.0000471
Bisser S, Lumbala C, Nguertoum E, Kande V, Flevaud L, Vatunga G, et al. Sensitivity and specificity of a prototype rapid diagnostic test for the detection of Trypanosoma brucei gambiense infection: a multi-centric prospective study. PLoS Negl Trop Dis. 2016;10:e0004608.
pubmed: 27058033
pmcid: 4825971
doi: 10.1371/journal.pntd.0004608
Compaoré CAF, Ilboudo H, Kaboré J, Kaboré JW, Camara O, Bamba M, et al. Analytical sensitivity of loopamp and quantitative real-time PCR on dried blood spots and their potential role in monitoring human African trypanosomiasis elimination. Exp Parasitol. 2020;219:108014.
doi: 10.1016/j.exppara.2020.108014
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159.
pubmed: 843571
doi: 10.2307/2529310
Mumba Ngoyi D, Ali Ekangu R, Mumvemba Kodi MF, Pyana PP, Balharbi F, Decq M, et al. Performance of parasitological and molecular techniques for the diagnosis and surveillance of gambiense sleeping sickness. PLoS Negl Trop Dis. 2014;8:e2954.
pubmed: 24921941
pmcid: 4055587
doi: 10.1371/journal.pntd.0002954
Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, Jannin JG. The human African trypanosomiasis specimen biobank: a necessary tool to support research of new diagnostics. PLoS Negl Trop Dis. 2012;6:e1571.
pubmed: 22761968
pmcid: 3385620
doi: 10.1371/journal.pntd.0001571
Inojosa WO, Augusto I, Bisoffi Z, Josenado T, Abel PM, Stich A, et al. Diagnosing human African trypanosomiasis in Angola using a card agglutination test: observational study of active and passive case finding strategies. BMJ. 2006;332:1479.
pubmed: 16777858
pmcid: 1482336
doi: 10.1136/bmj.38859.531354.7C
Lumbala C, Bessell PR, Lutumba P, Baloji S, Biéler S, Ndung’u JM. Performance of the SD BIOLINE HAT rapid test in various diagnostic algorithms for gambiense human African trypanosomiasis in the Democratic Republic of the Congo. PLoS One. 2017;12:e0180555.
pubmed: 28672036
pmcid: 5495481
doi: 10.1371/journal.pone.0180555
Camara O, Kaboré JW, Soumah A, Leno M, Bangoura MS, N’Diaye D, et al. Conducting active screening for human African trypanosomiasis with rapid diagnostic tests: the Guinean experience (2016–2021). PLoS Negl Trop Dis. 2024;18(2):e0011985.
pubmed: 38377123
pmcid: 10906848
doi: 10.1371/journal.pntd.0011985
Boelaert M, Mukendi D, Bottieau E, Kalo Lilo JR, Verdonck K, Minikulu L, et al. A Phase III diagnostic accuracy study of a rapid diagnostic test for diagnosis of second-stage human African trypanosomiasis in the Democratic Republic of the Congo. EBioMedicine. 2018;27:11–7.
pubmed: 29246478
doi: 10.1016/j.ebiom.2017.10.032
Camara O, Camara M, Falzon LC, Ilboudo H, Kaboré J, Compaoré CFA, et al. Performance of clinical signs and symptoms, rapid and reference laboratory diagnostic tests for diagnosis of human African trypanosomiasis by passive screening in Guinea: a prospective diagnostic accuracy study. Infect Dis Poverty. 2023;12(1):22.
pubmed: 36941656
pmcid: 10026442
doi: 10.1186/s40249-023-01076-1
Compaoré CFA, Kaboré J, Ilboudo H, Thomas LF, Falzon LC, Bamba M, et al. Monitoring the elimination of gambiense human African trypanosomiasis in the historical focus of Batié, South-West Burkina Faso. Parasite. 2022;29:25.
pubmed: 35543528
pmcid: 9093133
doi: 10.1051/parasite/2022024
Sullivan L, Wall SJ, Carrington M, Ferguson MAJ. Proteomic selection of immunodiagnostic antigens for human African trypanosomiasis and generation of a prototype lateral flow immunodiagnostic device. PLoS Negl Trop Dis. 2013;7:e2087.
pubmed: 23469310
pmcid: 3584999
doi: 10.1371/journal.pntd.0002087
Sternberg JM, Gierliński M, Biéler S, Ferguson MAJ, Ndung’u JM. Evaluation of the diagnostic accuracy of prototype rapid tests for human African trypanosomiasis. PLoS Negl Trop Dis. 2014;8:e3373.
pubmed: 25521120
pmcid: 4270746
doi: 10.1371/journal.pntd.0003373
Truc P, Büscher P, Cuny G, Gonzatti MI, Jannin J, Joshi P, et al. Atypical human infections by animal trypanosomes. PLoS Negl Trop Dis. 2013;7:e2256.
pubmed: 24069464
pmcid: 3772015
doi: 10.1371/journal.pntd.0002256
World Health Organization. Leishmaniasis. In: WHO global health observatory. World Health Organization; 2024. https://apps.who.int/neglected_diseases/ntddata/leishmaniasis/leishmaniasis.html . Accessed 6 June 2024.
Kouassi B, Horo K, Achi VH, Adoubryn KD, Kakou ES, Ahui B, et al. Three cases of visceral leishmaniasis in Abidjan, Cote d’Ivoire. Med Trop (Mars). 2005;65:602–3. (in French).
pubmed: 16555523
Olmer J. Adult Kala-azar observed in Côte-d’Ivoire. Bull Acad Natl Med. 1972;156:226–8 ((in French)).
pubmed: 4351424
Eholié SP, Tanon AK, Folquet-Amorissani M, Doukouré B, Adoubryn KD, Yattara A, et al. Three new cases of visceral leishmaniasis in Côte d’Ivoire. Bull Soc Pathol Exot. 2008;101:60–1 ((in French)).
pubmed: 18432012
Garcia A, Jamonneau V, Magnus E, Laveissière C, Lejon V, N’guessan P, et al. Follow-up of Card Agglutination Trypanosomiasis Test (CATT) positive but apparently aparasitaemic individuals in Côte d’Ivoire: evidence for a complex and heterogeneous population. Trop Med Int Health. 2000;5:786–93.
pubmed: 11123826
doi: 10.1046/j.1365-3156.2000.00623.x
Solano P, Jamonneau V, N’Guessan P, N’Dri L, Dje NN, Miezan TW, et al. Comparison of different DNA preparation protocols for PCR diagnosis of human African trypanosomosis in Côte d’Ivoire. Acta Trop. 2002;82:349–56.
pubmed: 12039674
doi: 10.1016/S0001-706X(02)00029-3
Moser DR, Cook GA, Ochs DE, Bailey CP, McKane MR, Donelson JE. Detection of Trypanosoma congolense and Trypanosoma brucei subspecies by DNA amplification using the polymerase chain reaction. Parasitology. 1989;99(1):57–66.
pubmed: 2797872
doi: 10.1017/S0031182000061023
Verney M, Grey F, Lemans C, Géraud T, Berthier D, Thévenon S, et al. Molecular detection of 7SL-derived small RNA is a promising alternative for trypanosomosis diagnosis. Transbound Emerg Dis. 2020;67:3061–8.
pubmed: 32687668
doi: 10.1111/tbed.13744
Contreras Garcia M, Walshe E, Steketee PC, Paxton E, Lopez-Vidal J, Pearce MC, et al. Comparative sensitivity and specificity of the 7SL sRNA diagnostic test for animal trypanosomiasis. Front Vet Sci. 2022;9:868912.
pubmed: 35450136
pmcid: 9017285
doi: 10.3389/fvets.2022.868912
World Health Organization. Criteria and procedures for the verification of elimination of transmission of T. b. gambiense to the human population in a given country. Geneva: World Health Organization; 2023.
KandeBetuKumeso V, KalonjiMutombo W, Rembry S, ValverdeMordt O, NgoloTete D, Prêtre A, et al. Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial. Lancet Infect Dis. 2023;23:463–70.
doi: 10.1016/S1473-3099(22)00660-0
Biéler S, Waltenberger H, Barrett MP, McCulloch R, Mottram JC, Carrington M, et al. Evaluation of antigens for development of a serological test for human African trypanosomiasis. PLoS One. 2016;11:e0168074.
pubmed: 27936225
pmcid: 5148118
doi: 10.1371/journal.pone.0168074
Lejon V, Bieler S, Camara O, N’Djetchi KM, Jamonneau V, Bart J-M, et al. Prospective evaluation of the specificity of serological tests for human African trypanosomiasis: documentation and data. DataSuds; 2022. https://doi.org/10.23708/APDHAG . Accessed 6 June 2024.